Combined Bigpharma Dealmaking and Agreements Handbook 2007

Abstract

The Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company' s business development objectives.

The initial chapters of this report provide an orientation of bigpharma' s dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2006 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers in 2005 and 2006 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-6 according to reported deal size.

Chapter 5 provides a summary on best practice on how to submit an opportunity to bigpharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner. Chapter 6 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a highly effective means of obtaining interest in novel opportunities.

The main body of the report is provided in chapter 7 and 8. Firstly, a series of matrices provide a cross reference for each bigpharma company versus therapy area with respect to marketed and pipeline activity, partnering interests, and partnering activity in the last two years. Secondly, in-depth profiles of every bigpharma company provide everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company' s marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. Each profile also includes in-depth contact information for individuals within the business development function.

In addition, each company profile provides a listing of deal contract documents available in the public domain, each of which can be obtained from CurrentPartnering, either individually or as part of a contract set. See each company profile for further details.

• A comprehensive overview of the partnering activities and interests of the leading fifty biopharma companies
• Identify prospective partner companies by analyzing their dealmaking activity and interests
• Undertake initial due diligence to assess suitability of partner companies
• Make direct contact with over 1,300 named business development executives
• Identify over 1,000 actual contract agreements entered into by the company and its partner companies
• Understand the key deal terms the company has agreed in previous deals

Bigpharma Dealmaking Handbook 2007 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company' s approach to partnering.

Bigpharma Dealmaking Handbook 2007 includes:

• The tools to enable effective and efficient partnering with bigpharma
• Detailed partnering activity and interests profiles for the leading fifty bigpharma companies
• Direct contact information for over 1,300 bigpharma dealmakers
• Listing of over 1,000 contract documents between bigpharma and partner companies
• The leading M&A and partnering deals by value 2005-6
• Most active M&A and partnering dealmakers 2005-6
• Guidelines on how to submit partnering opportunities to bigpharma
• The leading partnering resources and networking events

The Bigpharma Dealmaking Handbook 2007 provides a comprehensive profile for each of the fifty bigpharma companies, including:

• Detailed company profile
• In-depth marketed and pipeline activity of each company
• Partnering interests statement and therapy focus
• Partnering activity for 2005-2006
• Activity by deal type
• Activity by phase of development
• Activity by therapeutic area
• List of recent partner companies
• Direct contact information for dealmakers
• General company and partnering contact information
• List of contract documents available* to allow analysis of bigpharma deal terms

Number of pages: The report is comprised of 438 pages.